Piper Jaffray Companies began coverage on shares of CV Sciences (OTCMKTS:CVSI) in a research note issued to investors on Monday, BenzingaRatingsTable reports. The firm issued an overweight rating and a $5.00 target price on the stock. Piper Jaffray Companies also issued estimates for CV Sciences’ Q3 2019 earnings at $0.01 EPS, Q4 2019 earnings at $0.01 EPS, FY2019 earnings at ($0.04) EPS, Q1 2020 earnings at $0.01 EPS, Q2 2020 earnings at $0.02 EPS, Q3 2020 earnings at $0.03 EPS, Q4 2020 earnings at $0.04 EPS and FY2020 earnings at $0.10 EPS.
A number of other equities research analysts have also commented on the company. Roth Capital began coverage on CV Sciences in a research report on Thursday, May 16th. They issued a buy rating and a $9.00 target price on the stock. Zacks Investment Research lowered CV Sciences from a buy rating to a hold rating in a research report on Tuesday, June 18th. Finally, Northland Securities reiterated a buy rating on shares of CV Sciences in a research report on Thursday, May 9th.
Shares of OTCMKTS CVSI opened at $3.20 on Monday. The business’s 50 day moving average price is $3.91 and its 200 day moving average price is $4.72. The firm has a market cap of $317.04 million, a P/E ratio of 35.50 and a beta of -0.50. CV Sciences has a 52 week low of $2.76 and a 52 week high of $9.20. The company has a quick ratio of 2.43, a current ratio of 3.20 and a debt-to-equity ratio of 0.13.
CV Sciences (OTCMKTS:CVSI) last issued its earnings results on Tuesday, August 6th. The company reported $0.01 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.01. The firm had revenue of $16.85 million for the quarter, compared to analyst estimates of $17.45 million. CV Sciences had a negative return on equity of 6.47% and a negative net margin of 3.29%. As a group, research analysts expect that CV Sciences will post -0.04 earnings per share for the current year.
CV Sciences Company Profile
CV Sciences, Inc operates as a life science company. It operates through two segments, Consumer Products and Specialty Pharmaceuticals. The Consumer Products segment manufactures, markets, and sells consumer products containing hemp-based cannabidiol oil under the PlusCBD brand in various market sectors, including nutraceutical, beauty care, specialty foods, and vape.
Receive News & Ratings for CV Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CV Sciences and related companies with MarketBeat.com's FREE daily email newsletter.